Human trials have confirmed similar patterns, with participants showing metabolic rates that remained elevated despite significant weight loss
Final licensed dosing in the UK will be determined by the MHRA at the point of approval
The advantages of Wegovy are truly remarkable, including substantial weight reduction, improved blood sugar management for individuals with obesity, and a decreased likelihood of heart disease
Although epiploic appendagitis has not been identified as an adverse event or safety signal in randomized trials, systematic reviews, or pharmacovigilance analyses of GLP-1/GIP receptor agonists, it is biologically plausible that rapid weight loss could increase susceptibility to this condition
This mechanism: Increases urinary glucose excretion , effectively removing excess glucose from the body Produces a modest reduction in blood pressure through mild diuretic effects Offers cardiovascular and renal benefits in specific patient populations, as demonstrated in clinical trials and reflected in its licensed indications Results in modest weight loss (typically 2-3 kg) due to calorie loss through glucose excretion Because these medications work through completely different pathwaysone affecting gut hormones and appetite regulation, the other affecting kidney glucose handlingthey can complement each other when managing complex metabolic conditions
Diagnosing night sweats requires a medical evaluation to identify the cause
